These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1941051)

  • 1. Poorly differentiated carcinoma of unknown primary site: clinical usefulness of immunoperoxidase staining.
    Hainsworth JD; Wright EP; Johnson DH; Davis BW; Greco FA
    J Clin Oncol; 1991 Nov; 9(11):1931-8. PubMed ID: 1941051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
    Hainsworth JD; Greco FA
    Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
    Greco FA; Hainsworth JD
    Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.
    Hainsworth JD; Johnson DH; Greco FA
    J Clin Oncol; 1992 Jun; 10(6):912-22. PubMed ID: 1375284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of immunohistochemistry in patients with poorly differentiated adenocarcinomas and undifferentiated carcinomas of unknown primary.
    van der Gaast A; Verwij J; Planting AS; Stoter G; Henzen-Logmans SC
    J Cancer Res Clin Oncol; 1996; 122(3):181-85. PubMed ID: 8601568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site.
    Hainsworth JD; Lennington WJ; Greco FA
    J Clin Oncol; 2000 Feb; 18(3):632-5. PubMed ID: 10653878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
    Motzer RJ; Rodriguez E; Reuter VE; Bosl GJ; Mazumdar M; Chaganti RS
    J Clin Oncol; 1995 Jan; 13(1):274-82. PubMed ID: 7799031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poorly differentiated carcinoma and germ cell tumors.
    Hainsworth JD; Greco FA
    Hematol Oncol Clin North Am; 1991 Dec; 5(6):1223-31. PubMed ID: 1663941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Dial TW; Greco FA
    Am J Clin Oncol; 1988 Apr; 11(2):138-45. PubMed ID: 2451881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poorly differentiated neuroendocrine carcinoma of unknown primary site. A newly recognized clinicopathologic entity.
    Hainsworth JD; Johnson DH; Greco FA
    Ann Intern Med; 1988 Sep; 109(5):364-71. PubMed ID: 2841895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistological studies in five patients with unknown primary carcinomas and poorly differentiated neoplasms.
    Greenberg BR
    Ann Clin Lab Sci; 1989; 19(3):175-83. PubMed ID: 2658727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown origin: favorable subsets of patients with unknown-primary carcinoma?
    Lenzi R; Hess KR; Abbruzzese MC; Raber MN; Ordoñez NG; Abbruzzese JL
    J Clin Oncol; 1997 May; 15(5):2056-66. PubMed ID: 9164218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated carcinoma of unknown primary site: correlation of light microscopic findings with response to cisplatin-based combination chemotherapy.
    Hainsworth JD; Wright EP; Gray GF; Greco FA
    J Clin Oncol; 1987 Aug; 5(8):1275-80. PubMed ID: 2442318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoma of unknown primary site: treatment with 1-hour paclitaxel, carboplatin, and extended-schedule etoposide.
    Hainsworth JD; Erland JB; Kalman LA; Schreeder MT; Greco FA
    J Clin Oncol; 1997 Jun; 15(6):2385-93. PubMed ID: 9196154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma of unknown primary site.
    Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
    Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site.
    Hainsworth JD; Johnson DH; Greco FA
    Cancer; 1991 Jan; 67(1 Suppl):310-4. PubMed ID: 1984833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of types and primary sites of malignant tumors by examination of exfoliated tumor cells in serous fluids. Comparison with the diagnostic accuracy on small histologic biopsies.
    Spieler P; Gloor F
    Acta Cytol; 1985; 29(5):753-67. PubMed ID: 2996273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.